Small Cell Lung Cancer Entering the Sphere of Personalized Treatment
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 August 2024 | Viewed by 759
Special Issue Editors
Interests: cancer; lung cancer; DNA; RNA; miRNA; epigenetics; NGS; molecular testing
Special Issues, Collections and Topics in MDPI journals
Interests: lung cancer; oncology; NSCLC; non-small cell lung cancer; SCLC; small cell lung cancer; molecularly targeted therapy; immunotherapy; artificial intelligence
Interests: lung cancer; oncology; NSCLC; non-small cell lung cancer; SCLC; small cell lung cancer; molecularly targeted therapy; immunotherapy
Special Issue Information
Dear Colleagues,
Small cell lung cancer (SCLC) is a subtype of lung cancer, which is the most malignant, rapidly progressive and poorly prognostic cancer of the thoracic region. Overall survival is short, and therapeutic options are few. Until recently, the only systemic treatment was chemotherapy, which can cause serious adverse effects and has limited efficacy.
Recently, it became possible to use immune checkpoint inhibitors (ICIs) in combination with chemotherapy in therapy of SCLC patients. This is a big progress in the treatment of small cell lung cancer, where until now not much has been done in terms of modern therapies. Almost in parallel, we have scientific reports regarding broad-spectrum genomic and transcriptomic analysis in SCLC. There have been tremendous molecular advances in SCLC, which may provide the basis for designing and implementing targeted therapies, both with monoclonal antibodies and small-molecule therapies.
We greatly encourage scientific discussion on this very timely, extremely all-important and necessary topic.
Dr. Anna Grenda
Dr. Michał Szczyrek
Dr. Izabela Chmielewska
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- small cell lung cancer
- SCLC
- pathological subtypes
- molecular subtypes
- DNA
- RNA
- NGS
- next-generation sequencing transcriptome
- mutations
- molecular analysis
